Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

Add To Watchlist

Recent & Breaking News (NDAQ:GRCE)

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

PR Newswire July 10, 2023

Acasti Pharma Announces 1-for-6 Reverse Stock Split

PR Newswire July 7, 2023

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

PR Newswire July 5, 2023

Acasti Pharma Reports Fiscal Year 2023 Operational Results

PR Newswire June 23, 2023

Acasti Announces Appointment of New Scientific Advisory Board Members

PR Newswire June 22, 2023

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

PR Newswire May 17, 2023

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

PR Newswire May 8, 2023

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

PR Newswire April 4, 2023

Acasti Announces Appointment of Prashant Kohli as CEO

PR Newswire April 4, 2023

Acasti Pharma Inc. Announces the Resignation of a Director

PR Newswire March 30, 2023

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

PR Newswire March 13, 2023

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

PR Newswire March 8, 2023

Acasti Pharma Recognizes Rare Disease Day

PR Newswire February 28, 2023

Acasti Pharma Reports Third Quarter 2023 Operational Results

GlobeNewswire February 14, 2023

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

PR Newswire February 7, 2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

GlobeNewswire January 25, 2023

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

GlobeNewswire January 24, 2023

Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

Newsfile January 17, 2023

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

GlobeNewswire January 13, 2023

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

GlobeNewswire January 5, 2023